CN105200124A - 用于肿瘤特征和标记物组鉴定，肿瘤分级的方法和用于癌的标记物组 - Google Patents

用于肿瘤特征和标记物组鉴定，肿瘤分级的方法和用于癌的标记物组 Download PDF

Info

Publication number
CN105200124A
CN105200124A CN201510530687.4A CN201510530687A CN105200124A CN 105200124 A CN105200124 A CN 105200124A CN 201510530687 A CN201510530687 A CN 201510530687A CN 105200124 A CN105200124 A CN 105200124A
Authority
CN
China
Prior art keywords
gene expression
cancer
expression signal
group
random
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510530687.4A
Other languages
English (en)
Chinese (zh)
Inventor
E·王
李�杰
邓迎海
A·Eg·伦费林克
M·D·奥康纳-麦考特
E·普里西马
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Research Council of Canada
Original Assignee
National Research Council of Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Research Council of Canada filed Critical National Research Council of Canada
Publication of CN105200124A publication Critical patent/CN105200124A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/44—Multiple drug resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Organic Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Pathology (AREA)
  • Evolutionary Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201510530687.4A 2009-04-16 2010-04-16 用于肿瘤特征和标记物组鉴定，肿瘤分级的方法和用于癌的标记物组 Pending CN105200124A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20288109P 2009-04-16 2009-04-16
US61/202,881 2009-04-16
CN201080020971.2A CN102421920B (zh) 2009-04-16 2010-04-16 用于肿瘤特征和标记物组鉴定,肿瘤分级的方法和用于癌的标记物组

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201080020971.2A Division CN102421920B (zh) 2009-04-16 2010-04-16 用于肿瘤特征和标记物组鉴定,肿瘤分级的方法和用于癌的标记物组

Publications (1)

Publication Number Publication Date
CN105200124A true CN105200124A (zh) 2015-12-30

Family

ID=42982085

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201510530687.4A Pending CN105200124A (zh) 2009-04-16 2010-04-16 用于肿瘤特征和标记物组鉴定，肿瘤分级的方法和用于癌的标记物组
CN201080020971.2A Expired - Fee Related CN102421920B (zh) 2009-04-16 2010-04-16 用于肿瘤特征和标记物组鉴定,肿瘤分级的方法和用于癌的标记物组
CN201510530592.2A Pending CN105132544A (zh) 2009-04-16 2010-04-16 用于肿瘤特征和标记物组鉴定，肿瘤分级的方法和用于癌的标记物组

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201080020971.2A Expired - Fee Related CN102421920B (zh) 2009-04-16 2010-04-16 用于肿瘤特征和标记物组鉴定,肿瘤分级的方法和用于癌的标记物组
CN201510530592.2A Pending CN105132544A (zh) 2009-04-16 2010-04-16 用于肿瘤特征和标记物组鉴定，肿瘤分级的方法和用于癌的标记物组

Country Status (7)

Country Link
US (1) US20120040863A1 (https=)
EP (1) EP2419533A4 (https=)
JP (2) JP2012525818A (https=)
CN (3) CN105200124A (https=)
AU (1) AU2010237568A1 (https=)
CA (1) CA2758041A1 (https=)
WO (1) WO2010118520A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018219342A1 (zh) * 2017-06-01 2018-12-06 立森印迹诊断技术有限公司 一种印记基因分级模型和诊断方法及其应用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX338883B (es) 2010-07-27 2016-05-04 Genomic Health Inc Metodo para usar expresion de gen para determinar el pronostico de cancer de prostata.
CA2829776A1 (en) 2011-03-14 2012-09-20 National Research Council Of Canada Prognostic marker sets for prostate cancer
US12130290B2 (en) * 2016-11-29 2024-10-29 Trustees Of Tufts College Compositions and methods for diagnosing breast cancer
CN110890128B (zh) * 2018-09-10 2024-02-09 立森印迹诊断技术（无锡）有限公司 一种用于检测皮肤肿瘤良恶性程度的分级模型及其应用
JP7352937B2 (ja) * 2019-07-19 2023-09-29 公立大学法人福島県立医科大学 乳癌のサブタイプを鑑別又は分類するための鑑別マーカー遺伝子セット、方法およびキット
CN115064209B (zh) * 2022-08-17 2022-11-01 普瑞基准科技（北京）有限公司 一种恶性细胞鉴定方法及系统

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7955800B2 (en) * 2002-06-25 2011-06-07 Advpharma Inc. Metastasis-associated gene profiling for identification of tumor tissue, subtyping, and prediction of prognosis of patients
US8019552B2 (en) * 2004-03-05 2011-09-13 The Netherlands Cancer Institute Classification of breast cancer patients using a combination of clinical criteria and informative genesets
KR20070057761A (ko) * 2004-06-04 2007-06-07 아비아라디엑스, 인코포레이티드 종양의 확인방법
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
US20100234292A1 (en) * 2007-04-16 2010-09-16 Ipsogen Methods of assessing a propensity of clinical outcome for a female mammal suffering from breast cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018219342A1 (zh) * 2017-06-01 2018-12-06 立森印迹诊断技术有限公司 一种印记基因分级模型和诊断方法及其应用

Also Published As

Publication number Publication date
EP2419533A1 (en) 2012-02-22
JP2016073287A (ja) 2016-05-12
EP2419533A4 (en) 2014-12-31
AU2010237568A1 (en) 2011-11-17
CA2758041A1 (en) 2010-10-21
WO2010118520A1 (en) 2010-10-21
CN105132544A (zh) 2015-12-09
CN102421920B (zh) 2015-09-30
JP2012525818A (ja) 2012-10-25
CN102421920A (zh) 2012-04-18
US20120040863A1 (en) 2012-02-16

Similar Documents

Publication Publication Date Title
Heitzer et al. Current and future perspectives of liquid biopsies in genomics-driven oncology
Biswas et al. A clonal expression biomarker associates with lung cancer mortality
Li et al. Identification of a five‐lncRNA signature for predicting the risk of tumor recurrence in patients with breast cancer
Modlin et al. Neuroendocrine tumor biomarkers: From monoanalytes to transcripts and algorithms
Mehta et al. Predictive and prognostic molecular markers for cancer medicine
Mordente et al. Cancer biomarkers discovery and validation: state of the art, problems and future perspectives
Lin et al. Molecular classification and prediction in gastric cancer
Font et al. BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer
Velmahos et al. Using deep learning to identify bladder cancers with FGFR‐activating mutations from histology images
Alsaleem et al. A novel prognostic two-gene signature for triple negative breast cancer
Herrgott et al. Detection of diagnostic and prognostic methylation-based signatures in liquid biopsy specimens from patients with meningiomas
JP2021521536A (ja) 生体試料の多検体アッセイのための機械学習実装
Mitra et al. Prediction of postoperative recurrence-free survival in non–small cell lung cancer by using an internationally validated gene expression model
Wang et al. Dissecting the heterogeneity of the alternative polyadenylation profiles in triple-negative breast cancers
AU2019250606B2 (en) Improved classification and prognosis of prostate cancer
CN102421920B (zh) 用于肿瘤特征和标记物组鉴定,肿瘤分级的方法和用于癌的标记物组
Liu et al. Identification and validation of gene module associated with lung cancer through coexpression network analysis
Yadavalli et al. Data-driven discovery of extravasation pathway in circulating tumor cells
Reggiardo et al. LncRNA biomarkers of inflammation and cancer
US20090221522A1 (en) Methods to correct gene set expression profiles to drug sensitivity
Wang et al. Identification of blood-derived exosomal tumor RNA signatures as noninvasive diagnostic biomarkers for multi-cancer: a multi-phase, multi-center study
CN108513587A (zh) 对转移性疾病具有预测性的基因标签
Wang et al. A robust blood gene expression-based prognostic model for castration-resistant prostate cancer
Sun et al. Genomic instability-associated lncRNA signature predicts prognosis and distinct immune landscape in gastric cancer
Zhou et al. Identification of small nucleolar RNA SNORD60 as a potential biomarker and its clinical significance in lung adenocarcinoma

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20151230

WD01 Invention patent application deemed withdrawn after publication